Enhertu as Second-Line Therapy for HER2-Positive Advanced Gastric Cancer

On September 18, 2021, AstraZeneca announced the results of the DESTINY-Gastric02 Phase 2 clinical trial, evaluating Enhertu (Trastuzumab deruxtecan) as a second-line therapy for patients with HER2-positive advanced gastric cancer. The findings were presented at the ESMO Congress 2021.

Study Design: DESTINY-Gastric02 Trial

DESTINY-Gastric02 is an international, multicenter, open-label, single-arm Phase 2 trial. It enrolled patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer who had progressed on or after a trastuzumab-containing regimen.

Patients received Enhertu at a dose of 6.4 mg/kg every three weeks. The primary endpoint was objective response rate (ORR).

Key Efficacy Results (Median Follow-up 5.7 Months)

• Objective Response Rate (ORR): 38.0%
  • Complete Response (CR): 3.8%
  • Partial Response (PR): 34.2%
• Disease Control Rate (DCR): 81.0%
• Median Duration of Response (DOR): 8.1 months
• Median Progression-Free Survival (PFS): 5.5 months

Safety Profile

The safety profile was consistent with previous trials of Enhertu. The most common Grade 3 or higher adverse events included:

• Anemia: 7.6%
• Neutropenia: 7.6%
• Interstitial Lung Disease (ILD): 7.6% (N=6 patients)
• Nausea and Fatigue: 3.8% each

Most adverse events were Grade 1 or 2.

Conclusion

Dr. Eric Van Cutsem from University Hospitals Leuven concluded that Enhertu demonstrates a clinically meaningful response in patients with HER2-positive advanced gastric cancer who have failed prior treatment, establishing its role as a potent second-line option.

Source: AstraZeneca Press Release - DESTINY-Gastric02 Results

#GastricCancer #HER2Positive #Enhertu #TDXd #DESTINYGastric02 #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4